• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
Deferasirox

Deferasirox

Product ID D1621
Cas No. 201530-41-8
Purity ≥99%
Product Unit SizeCostQuantityStock
25 mg $101.00 In stock
100 mg $370.90 In stock
250 mg $718.60 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Deferasirox is an iron chelator commonly used to treat iron-overload disease. Deferasirox also displays both neuroprotective and chemotherapeutic benefit as well. This compound exhibits neuroprotective activity in both in vitro and in vivo models of stroke/ischemia conditions. In vitro, deferasirox increases expression of metastasis suppressing genes, p21, caspase-3, and PARP and decreases levels of cyclin D1 and activity of NF-κB. The ability of deferasirox to inhibit iron uptake decreases tumor growth in animal models of cancer.

Product Info

Cas No.

201530-41-8

Purity

≥99%

Formula

C21H15N3O4

Formula Wt.

373.63

Chemical Name

4-[3,5-Bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]- benzoic Acid

IUPAC Name

4-[(3Z,5E)-3,5-bis(6-oxocyclohexa-2,4-dien-1-ylidene)-1,2, 4-triazolidin-1-yl]benzoic acid

Synonym

ICL670A, CGP 72 670

Appearance

White to off white powder

Shipping and Storage

Store Temp

Ambient

Ship Temp

Ambient

Downloads

MSDS

D1621 MSDS PDF

Info Sheet

D1621 Info Sheet PDF

References

Vazana-Barad L, Granot G, Mor-Tzuntz R, et al. Mechanism of the antitumoral activity of deferasirox, an iron chelation agent, on mantle cell lymphoma. Leuk Lymphoma. 2013 Apr;54(4):851-9. PMID: 23020673.

Lui GY, Obeidy P, Ford SJ, et al. The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action. Mol Pharmacol. 2013 Jan;83(1):179-90. PMID: 23074173.

Zhao Y, Rempe DA. Prophylactic neuroprotection against stroke: low-dose, prolonged treatment with deferoxamine or deferasirox establishes prolonged neuroprotection independent of HIF-1 function. J Cereb Blood Flow Metab. 2011 Jun;31(6):1412-23. PMID: 21245873.

Messa E, Carturan S, Maffè C, et al. Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. Haematologica. 2010 Aug;95(8):1308-16. PMID: 20534700.

Lindsey WT, Olin BR. Deferasirox for transfusion-related iron overload: a clinical review. Clin Ther. 2007 Oct;29(10):2154-66. PMID: 18042472.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • L0350

    Lamivudine

    Nucleoside (thymidine) analog; RT inhibitor.

    ≥99%
  • V9201

    VX-11e

    ERK2 inhibitor, potential AurKA, GSK3, CDK2, FL...

    ≥98%
  • T1670

    Terazosin Hydrochloride Dihydrate

    Quinazoline; α1-adrenergic antagonist.

    ≥98%
  • G0278

    Gatifloxacin Sesquihydrate

    Fluoroquinolone; bacterial DNA gyrase inhibitor...

    ≥98%
  • M5876

    Motesanib

    VEGFR1/2/3, PDGFR, c-Kit, RET inhibitor.

    ≥98%
  • A5037

    Amiodarone Hydrochloride

    Voltage-gated Na+, Ca2+, K+ channel blocker, α...

    ≥98%
  • A4521

    Alfacalcidol

    Vitamin D analog.

    ≥98%
  • M400005

    MK-5108 Hydrochloride

    Aurora kinase A inhibitor.

    ≥98%
  • B807214

    Buflomedil Hydrochloride

    Alpha blocker and vasoactive agent.

    ≥99%
  • R6052

    Recombinant Mycoplasma Pneumonia Antigen

    Pneumonia antigen

  • O9210

    Oxcarbazepine

    α4β2 nAChR desensitizer, delayed-rectifier vo...

    ≥98%
  • A7332

    Asiatic Acid, 95%

    Triterpene aglycone originally found in Centell...

    ≥95%
  • K7602

    KT5823

    PKG inhibitor.

    ≥98%
  • F1853

    Fenofibrate

    Fibrate; PPARα agonist.

    ≥98%
  • E7556

    Etodolac

    NSAID; TRPA1 agonist, COX-2 inhibitor.

    ≥98%
  • P0001

    P1 Peptide

    Octapeptide, prevents EGFR-PLCγ association.

    ≥95%
  • R2714

    Recombinant HCV-NS5 Antigens

    Recombinant HCV antigen fragment.

    ≥95%
  • C9880

    Cytochalasin C

    Mycotoxin produced by Aspergillus; actin polyme...

    ≥98%, TLC
  • G7862

    GTPL-5846

    GPR84 agonist.

    ≥98%
  • G0152

    Ganciclovir

    Nucleoside (guanosine) analog; DNA chain termin...

    ≥98%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only